131 related articles for article (PubMed ID: 31357743)
1. EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.
Mahmud Z; Gomes AR; Lee HJ; Aimjongjun S; Jiramongkol Y; Yao S; Zona S; Alasiri G; Gong G; Yagüe E; Lam EW
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357743
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.
Aimjongjun S; Mahmud Z; Jiramongkol Y; Alasiri G; Yao S; Yagüe E; Janvilisri T; Lam EW
BMC Cancer; 2019 Nov; 19(1):1106. PubMed ID: 31727006
[TBL] [Abstract][Full Text] [Related]
3. The interaction between acetylation and serine-574 phosphorylation regulates the apoptotic function of FOXO3.
Li Z; Bridges B; Olson J; Weinman SA
Oncogene; 2017 Mar; 36(13):1887-1898. PubMed ID: 27669435
[TBL] [Abstract][Full Text] [Related]
4. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
5. Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells.
Alasiri G; Jiramongkol Y; Zona S; Fan LY; Mahmud Z; Gong G; Lee HJ; Lam EW
Oncogene; 2019 Sep; 38(36):6382-6398. PubMed ID: 31312024
[TBL] [Abstract][Full Text] [Related]
6. Characterization of FOXO Acetylation.
Yao S; Mahmud Z; Sachini N; Aimjongjun S; Saavedra-García P; Lam EW
Methods Mol Biol; 2019; 1890():77-90. PubMed ID: 30414146
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Hu JQ; Deng F; Hu XP; Zhang W; Zeng XC; Tian XF
Oncol Rep; 2018 Dec; 40(6):3635-3644. PubMed ID: 30542728
[TBL] [Abstract][Full Text] [Related]
8. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
[TBL] [Abstract][Full Text] [Related]
10. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Zhang L; Cai M; Gong Z; Zhang B; Li Y; Guan L; Hou X; Li Q; Liu G; Xue Z; Yang MH; Ye J; Chin YE; You H
J Clin Invest; 2017 Jun; 127(6):2159-2175. PubMed ID: 28436938
[TBL] [Abstract][Full Text] [Related]
11. Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib.
Li Z; Yang SS; Yin PH; Chang T; Shi LX; Fang L; Fang GE
Thorac Cancer; 2015 Nov; 6(6):695-703. PubMed ID: 26557906
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of icariin-mediated SIRT1/FOXO3 signaling pathway on intestinal ischemia/reperfusion-induced acute lung injury.
Zhang F; Li ZL; Xu XM; Hu Y; Yao JH; Xu W; Jing HR; Wang S; Ning SL; Tian XF
Mol Med Rep; 2015 Jan; 11(1):269-76. PubMed ID: 25323330
[TBL] [Abstract][Full Text] [Related]
13. Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells.
Liang R; Rimmelé P; Bigarella CL; Yalcin S; Ghaffari S
Cell Cycle; 2016; 15(6):861-7. PubMed ID: 26929388
[TBL] [Abstract][Full Text] [Related]
14. HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.
Lee HJ; Shin S; Kang J; Han KC; Kim YH; Bae JW; Park KH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942617
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an integrative network of microRNAs and transcriptomics changes for acute kidney injury.
Lee CG; Kim JG; Kim HJ; Kwon HK; Cho IJ; Choi DW; Lee WH; Kim WD; Hwang SJ; Choi S; Kim SG
Kidney Int; 2014 Nov; 86(5):943-53. PubMed ID: 24759152
[TBL] [Abstract][Full Text] [Related]
16. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
17. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
18. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
19.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
20. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Ma Z; Xing Y; Liu B; Edgerton SM; Thor AD; Yang X
Oncotarget; 2017 Aug; 8(35):58847-58864. PubMed ID: 28938602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
